XML 27 R14.htm IDEA: XBRL DOCUMENT
v3.26.1

Balance Sheet Components | 3 Months Ended
--- | ---
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Balance Sheet Components | Balance Sheet Components Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consists of the following (in thousands):
| As of
| March 31, 2026 |  | December 31, 2025
Accrued compensation | $ | 9,218 |  |  | $ | 32,179 |
Accrued clinical and other research & development costs | 21,475 |  |  | 22,283 |
Accrued manufacturing costs | 9,031 |  |  | 5,336 |
Operating lease liability, current | 9,769 |  |  | 9,463 |
Finance lease liability, current | 90 |  |  | 83 |
Deferred research and development funding liability, current | 15,116 |  |  | 21,101 |
Other accrued costs and current liabilities | 5,077 |  |  | 7,401 |
Total accrued expenses and other current liabilities | $ | 69,776 |  |  | $ | 97,846 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration